RedHill Biopharma (RDHL) Tops Q2 EPS by 6c, Revenue Misses Consensus

RedHill Biopharma (NASDAQ: RDHL) reported Q2 EPS of ($0.06), $0.06 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $21.5 million versus the consensus estimate of $25.02 million.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• Northeast Indiana Bancorp, Inc. (NIDB) Reports Q1 EPS of $0.30
• Expro Group Holdings N.V. (XPRO) Reports In-Line Q1 EPS, provides guidance